Company: PRTA
Filing Date: 2025-03-28
Form Type: DEF 14A
Source: 0001559053-25-000017
Chunk: 14

Company: PROTHENA CORP PUBLIC LTD CO
Filing Date: 2025-03-28
Form: DEF 14A
Chunk 14
---
 If elected by our shareholders at the Annual Meeting, Ms. Cobb, Dr. Ekman, and Dr. Kinney will each hold office from the date of their election until no later than the third subsequent annual general meeting of shareholders (i.e., in 2028), or until their earlier death, resignation, or removal.

In order to be elected as a director, each nominee must receive the affirmative vote of a majority of the votes cast in person or by proxy at the Annual Meeting; if a director nominee does not receive this majority vote, such nominee will not be elected to the Board. In the event that any nominee becomes unavailable for election as a result of an unexpected occurrence, the proxy holders may vote your shares for the election of any substitute nominee whom the Board proposes. Each person nominated for election has consented to being named as a nominee in this Proxy Statement and agreed to serve if elected, and management has no reason to believe that any nominee will be unable to serve.

| 2025 PROXY STATEMENT |     | 7 |

TABLE OF CONTENTS

| PROPOSAL NO. 1 – ELECTION OF DIRECTORS |

The table below is provided to highlight the specific skills, qualifications, and other attributes of our director nominees and continuing directors. The lack of a mark for a particular item for a particular director does not mean the director lacks that skill or qualification; rather, a mark indicates a specific area of focus or expertise for which the Board relies on such director most. Also provided are summary statistics regarding the composition of the Board.

Following the table below is certain biographical information for each nominee for director and each director whose term as a director will continue after the Annual Meeting, which includes information regarding each person’s individual experience, qualifications, attributes, or skills that led the Board to conclude that such person should serve as a director, in light of our business and structure.

| Skills and Qualifications                                                                                              |     | Paula K. Cobb |     | Richard T. Collier |     | Shane M. Cooke |     | William H. Dunn, Jr. |     | Lars G. Ekman |     | Helen S. Kim |     | Gene G. Kinney |     | Dennis J. Selkoe |     | Daniel G. Welch |
| Science & Research                                                                                                     
 Scientific expertise in biopharmaceutical research and/or in relevant medical fields                                   |     |               |     |                    |     |                |     | l                    |     | l             |     |              |     |